Semaglutide is an injectable medication that treats type 2 diabetes and obesity by regulating blood sugar levels. A ...

Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic® (semaglutide 1.0 mg) ...

Ozempic (semaglutide ... given as a subcutaneous injection. Dosages can vary from person to person. Ozempic belongs to a drug class called glucagon-like peptide-1 receptor agonists (GLP-1 agonists).

Ozempic comes as a solution inside an injection ... is semaglutide. (An active ingredient is what makes a drug work.) Ozempic belongs to a group of drugs called glucagon-like peptide-1 (GLP ...

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

Ozempic injection pens come with disposable single ... of semaglutide lost more weight than those who took 1 mg of semaglutide. Semaglutide is the active ingredient in both Wegovy and Ozempic.

Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this.

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

Novo Nordisk (NVO) presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic injection 1 mg in adults ...

Semaglutide medications like Ozempic and Wegovy have exploded in popularity ... a recent study by the University of British Columbia linked GLP-1 (glucagon-like peptide-1) agonists — the class ...